AC Immune (NASDAQ:ACIU) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday, ValuEngine reports.

ACIU has been the topic of several other research reports. Zacks Investment Research cut shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub upgraded shares of AC Immune from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Monday, February 4th. They noted that the move was a valuation call. Finally, UBS Group downgraded shares of AC Immune from a “buy” rating to a “neutral” rating in a report on Friday, February 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $12.35.

AC Immune stock opened at $4.83 on Tuesday. AC Immune has a 1-year low of $3.25 and a 1-year high of $17.40. The stock has a market cap of $339.15 million, a PE ratio of -5.89 and a beta of 0.03.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Thursday, March 21st. The company reported ($0.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.55 by ($0.77). AC Immune had a negative net margin of 706.11% and a negative return on equity of 33.97%. The business had revenue of $1.41 million for the quarter, compared to the consensus estimate of $56.97 million. As a group, research analysts predict that AC Immune will post 0.75 EPS for the current year.

A number of institutional investors have recently modified their holdings of ACIU. Barclays PLC boosted its holdings in shares of AC Immune by 726.2% in the 4th quarter. Barclays PLC now owns 6,378 shares of the company’s stock valued at $61,000 after acquiring an additional 5,606 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of AC Immune in the third quarter valued at about $107,000. GSA Capital Partners LLP acquired a new stake in shares of AC Immune in the third quarter valued at about $110,000. Squarepoint Ops LLC acquired a new stake in AC Immune during the fourth quarter worth about $121,000. Finally, JPMorgan Chase & Co. acquired a new stake in AC Immune during the third quarter worth about $142,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Read More: Do investors pay a separate front-end load every time they buy additional shares?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.